吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究

Combined Gemcitabine and Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer:a Clinical Trial

目的观察吉西他滨(gemcitabine,GEM)联合顺铂方案治疗晚期非小细胞肺癌的疗效及不良反应.方法对经病理组织学或细胞学诊断证实的56例晚期非小细胞肺癌患者采用GP方案行静脉化疗:GEM 1000 mg/m2,静脉滴注,d1,d8;DDP 30mg/m2,静脉滴注,d1～d3;21天重复,至少治疗2个周期.结果可评价疗效56例,完全缓解(CR)5.3%(3/56),部分缓解(PR)42.9%(24/56),稳定(SD)33.9%(19/56),进展(PD)17.9%(10/56),总有效率(RR)48.2%(27/56);肿瘤控制率(CR+PR+SD)为82.1%(46/56);中位缓解期7.4个月,中位生存期11.3个月;不良反应以白细胞及血小板减少,消化道反应,乏力为常见,患者均可耐受,无化疗相关死亡.结论吉西他滨联合顺铂对晚期非小细胞肺癌有较好疗效,不良反应可为患者所耐受,值得临床应用.

Objective To evaluate the clinical efficacy and toxicity of advanced non-small cell lung cancer（NSCLC） treated by combined gemcitabine and cisplatin. Methods Fifty-six patients with advancd NSCLC enrolled in allotted to the study. The patients received gemcitabine 1 000 mg/m^2 on dl,d8 and cisplatin 30 mg/m2on d1-d3 in the 21-day eycle. Results An objective response was obtained in 48.2% （RR27/56） of patients（3 CR and 24 PR）, whereas 19 patients had setable disease and 10 patients showed progressive disease. The cancer control rate was 82.1% （CR ＋ PR ＋ SD）. The median response duration was 7.4 months and the median survival duration was 11.3 months. The main toxicities were leukopenia, thrombocytopenia,gastro-intertinal reaction and weakness. Conclusion The combination of gemcitabine and cisplatin, being feasible and well-tolerated, should be taken as an energetic scheme in the treatment of advanced NSCLC.